National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Revlimid® for the treatment of adult patients with previously untreated multiple myelomas (MM) who are not eligible for transplant (licence extension).

Rapid Review

Commenced Completed Outcome
05/10/2015 20/11/2015 Full Pharmacoeconomic Evaluation Recommended at submitted price.

Approved following confidential price negotiation for lenalidomide across all licensed indications (January 2018).